Abstract
Several direct oral anticoagulants (DOACs) are now widely used in the prevention and treatment of thromboembolic events. Unlike vitamin K antagonists, DOACs exhibit predictable pharmacokinetics and pharmacodynamics. DOACs are to be administered at fixed doses without routine coagulation monitoring. However, in some patient populations or specific clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients with a haemorrhagic or thromboembolic event during treatment with an anticoagulant, in those with acute renal failure, or in patients who require urgent surgery. This article provides practical guidance on laboratory testing of DOACs in routine practice and summarizes the influence of DOACs on commonly used coagulation assays.
Translated title of the contribution | Why, when and how monitor new oral anticoagulants? |
---|---|
Original language | French |
Pages (from-to) | 326-333 |
Number of pages | 8 |
Journal | Revue médicale suisse |
Volume | 10 |
Issue number | 416 |
Publication status | Published - 5 Feb 2014 |
Keywords
- Administration, Oral
- Anticoagulants
- Blood Coagulation Tests
- Drug Monitoring
- Humans
- Kidney Failure, Chronic
Fingerprint
Dive into the research topics of 'Why, when and how monitor new oral anticoagulants?'. Together they form a unique fingerprint.Student theses
-
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Douxfils, J. (Author), Dogne, J.-M. (Supervisor), Mullier, F. (Supervisor), Masereel, B. (President), Chatelain, B. (Jury), Chatelain, C. (Jury), Verhamme, P. (Jury), TEN CATE, H. (Jury) & Ageno, W. (Jury), 24 Oct 2015Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences